trial
as of 2026-07-01Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia
NCTId NCT04268303
at a glance
Phase 3 · Completed
Enrollment 380 (actual)
Sponsored by BioXcel Therapeutics Inc
Primary completion 2020-05-06
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 3
Status
Completed
Enrollment
380 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2020-01-24
Primary completion
2020-05-06
Eligibility
ALL · 18 Years · 75 Years
Interventions & indications
Sponsors
BioXcel Therapeutics IncLead Sponsor
Cognitive Research CorporationCollaborator
Investigators
1
Robert Risinger, MDStudy Chair
Sites
15 total
Little Rock, United StatesCerritos, United StatesCulver City, United StatesLong Beach, United StatesOrange, United StatesMiami Lakes, United StatesChicago, United StatesGaithersburg, United StatesLas Vegas, United StatesBerlin, United StatesMarlton, United StatesCharleston, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
380
Phase
PHASE3
Primary Completion Date
2020-05-06
Status
COMPLETED
relationships
The graph out of here
lead_sponsor
company
collaborator
indication
indication
indication
indication
investigator
person